TY - JOUR
T1 - Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge
AU - Whitlock, Gregory C.
AU - Deeraksa, Arpaporn
AU - Qazi, Omar
AU - Judy, Barbara M.
AU - Taylor, Katherine
AU - Propst, Katie L.
AU - Duffy, Angie J.
AU - Johnson, Kate
AU - Kitto, G. Barrie
AU - Brown, Katherine A.
AU - Dow, Steven W.
AU - Torres, Alfredo G.
AU - Estes, D. Mark
N1 - Funding Information:
This work was supported by NIH National Institute of Allergy and Infectious Diseases, Western Regional Center for Biodefense and Emerging Infections (D.M.E., A.G.T and K.A.B) and a fellowship award to G.C.W. from the UTMB Sealy Center for Vaccine Development. The work was also supported by NIH-NIAID grant U54 AI065357 (KP, AD, SD).
PY - 2010
Y1 - 2010
N2 - Burkholderia mallei and B. pseudomallei are Gram-negative pathogenic bacteria, responsible for the diseases glanders and melioidosis, respectively. Furthermore, there is currently no vaccine available against these Burkholderia species. In this study, we aimed to identify protective proteins against these pathogens. Immunization with recombinant B. mallei Hcp1 (type VI secreted/structural protein), BimA (autotransporter protein), BopA (type III secreted protein), and B. pseudomallei LolC (ABC transporter protein) generated significant protection against lethal inhaled B. mallei ATCC23344 and B. pseudomallei 1026b challenge. Immunization with BopA elicited the greatest protective activity, resulting in 100% and 60% survival against B. mallei and B. pseudomallei challenge, respectively. Moreover, sera from recovered mice demonstrated reactivity with the recombinant proteins. Dendritic cells stimulated with each of the different recombinant proteins showed distinct cytokine patterns. In addition, T cells from immunized mice produced IFN-γ following in vitro re-stimulation. These results indicated therefore that it was possible to elicit cross-protective immunity against both B. mallei and B. pseudomallei by vaccinating animals with one or more novel recombinant proteins identified in B. mallei.
AB - Burkholderia mallei and B. pseudomallei are Gram-negative pathogenic bacteria, responsible for the diseases glanders and melioidosis, respectively. Furthermore, there is currently no vaccine available against these Burkholderia species. In this study, we aimed to identify protective proteins against these pathogens. Immunization with recombinant B. mallei Hcp1 (type VI secreted/structural protein), BimA (autotransporter protein), BopA (type III secreted protein), and B. pseudomallei LolC (ABC transporter protein) generated significant protection against lethal inhaled B. mallei ATCC23344 and B. pseudomallei 1026b challenge. Immunization with BopA elicited the greatest protective activity, resulting in 100% and 60% survival against B. mallei and B. pseudomallei challenge, respectively. Moreover, sera from recovered mice demonstrated reactivity with the recombinant proteins. Dendritic cells stimulated with each of the different recombinant proteins showed distinct cytokine patterns. In addition, T cells from immunized mice produced IFN-γ following in vitro re-stimulation. These results indicated therefore that it was possible to elicit cross-protective immunity against both B. mallei and B. pseudomallei by vaccinating animals with one or more novel recombinant proteins identified in B. mallei.
KW - BPZE1
KW - Bordetella pertussis
KW - BrkA autotransporter
KW - Enterovirus 71
KW - Live mucosal vaccine
UR - http://www.scopus.com/inward/record.url?scp=77950660656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950660656&partnerID=8YFLogxK
U2 - 10.1016/j.provac.2010.03.013
DO - 10.1016/j.provac.2010.03.013
M3 - Article
AN - SCOPUS:77950660656
SN - 1877-282X
VL - 2
SP - 73
EP - 77
JO - Procedia in Vaccinology
JF - Procedia in Vaccinology
IS - 1
ER -